全文获取类型
收费全文 | 3183篇 |
免费 | 105篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 53篇 |
妇产科学 | 29篇 |
基础医学 | 77篇 |
口腔科学 | 2篇 |
临床医学 | 529篇 |
内科学 | 1455篇 |
皮肤病学 | 2篇 |
神经病学 | 28篇 |
特种医学 | 141篇 |
外科学 | 384篇 |
综合类 | 335篇 |
预防医学 | 108篇 |
眼科学 | 1篇 |
药学 | 121篇 |
2篇 | |
中国医学 | 6篇 |
肿瘤学 | 35篇 |
出版年
2024年 | 1篇 |
2023年 | 46篇 |
2022年 | 95篇 |
2021年 | 91篇 |
2020年 | 107篇 |
2019年 | 112篇 |
2018年 | 105篇 |
2017年 | 65篇 |
2016年 | 69篇 |
2015年 | 86篇 |
2014年 | 281篇 |
2013年 | 214篇 |
2012年 | 169篇 |
2011年 | 192篇 |
2010年 | 153篇 |
2009年 | 193篇 |
2008年 | 184篇 |
2007年 | 194篇 |
2006年 | 183篇 |
2005年 | 123篇 |
2004年 | 94篇 |
2003年 | 80篇 |
2002年 | 69篇 |
2001年 | 74篇 |
2000年 | 44篇 |
1999年 | 52篇 |
1998年 | 29篇 |
1997年 | 35篇 |
1996年 | 25篇 |
1995年 | 20篇 |
1994年 | 28篇 |
1993年 | 20篇 |
1992年 | 15篇 |
1991年 | 10篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1972年 | 2篇 |
排序方式: 共有3321条查询结果,搜索用时 15 毫秒
1.
目的应用左心室压力-应变环(PSL)量化评价左心室射血分数(LVEF)正常的心房颤动患者射频消融术前、术后的左心室心肌做功指数。 方法这是一项回顾性研究。选取2020年1月至2020年12月于安徽医科大学第二附属医院就诊的LVEF正常的持续性心房颤动患者37例,所有患者均行心房颤动射频消融术。另选取同期37例健康者为对照组。所有心房颤动患者均在射频消融术前及术后3~6个月内行超声心动图检查。采集并获取心房颤动患者及对照组的常规超声心动图参数,以及左心室整体纵向应变(GLS)、整体做功指数(GWI)、整体有效功(GCW)、整体无效功(GWW)、整体做功效率(GWE),分析比较心房颤动患者术前、术后及对照组3组的常规超声心动图参数以及压力-应变参数的差异。 结果心房颤动患者术前、术后及对照组LVEF比较,差异无统计学意义(P>0.05)。心房颤动组术前GLS、GWI、GCW及GWE低于对照组,GWW高于对照组,差异均有统计学意义(P均<0.05)。与术前比较,心房颤动组射频消融术后的GLS、GWI、GCW及GWE升高,GWW减低(P均<0.05);术后参数与对照组比较,GLS、GWI、GCW差异均无统计学意义(P均>0.05);但GWW高于对照组、GWE低于对照组,差异均有统计学意义(P均<0.05)。 结论PSL可以定量评估LVEF正常的心房颤动患者术前及术后的左心室心肌做功改变,早期检测持续性心房颤动患者的心肌受损情况。早期行射频消融术恢复窦性心律,可以有效改善此类患者早期心肌受损。 相似文献
2.
目的评价腔内治疗腹主-双髂动脉闭塞性疾病(ABIOD)的安全性及有效性。方法搜集2016年6月至2020年6月经CT血管造影(CTA)或数字减影血管造影(DSA)明确诊断的22例ABIOD患者的临床资料及影像学资料。急性闭塞患者行对吻支架置入术,考虑新鲜血栓形成患者给予置管溶栓术治疗后复查造影后行支架置入术。术后随访观察患者术后并发症、症状改善情况。评价血管腔内治疗ABIOD的安全性、有效性。结果 9例支架置入前行置管溶栓治疗,13例直接行支架置入术。22例患者均成功置入支架,20例患者置入KISS对吻支架,2例置入双侧髂动脉支架,共置入支架60枚,技术成功率100%。13例住院期间下肢缺血症状消失,8例住院期间下肢缺血症状明显改善,1例术后出现肝、肾功能衰竭死亡。术后3天患者平均踝肱指数(ABI)为0.92±0.08,较术前0.22±0.13明显提高,差异存在统计学意义(P<0.05),术后6个月Rutherford临床分级为0.33±0.58,较术前3.81±0.60明显降低,差异存在统计学意义(P<0.05)。术后随访时间9~57个月,平均(32.14±14.88)个... 相似文献
3.
导管相关血流感染是PICC严重的并发症之一,影响患者治疗及预后。该文从PICC相关血流感染风险预测模型的构建过程、基本情况、预测性能等方面进行综述,以期为国内PICC相关血流感染风险预测模型的构建及应用提供借鉴。 相似文献
4.
《Revista portuguesa de cardiologia》2022,41(9):783-789
Amiodarone is the most potent antiarrhythmic drug available and is commonly prescribed to treat and prevent not only life-threatening ventricular arrhythmias but also atrial fibrillation (AF). The latest European Society of Cardiology AF guidelines state that amiodarone is recommended for long-term rhythm control in all AF patients but that other antiarrhythmic drugs should be considered first whenever possible, due to its extracardiac toxicity. In patients without significant or with only minimal structural heart disease, amiodarone is not listed as a possibility in their therapeutic scheme. Still, amiodarone is widely and liberally used, and is the most prescribed antiarrhythmic drug for patients with AF despite its high toxicity profile. Non-cardiovascular death was more frequent with amiodarone treatment than with a rate control strategy in AFFIRM, while meta-analyses suggest an association between amiodarone use in patients without structural heart disease and increased non-cardiovascular mortality. Severe or even fatal outcomes due to amiodarone may occur years after treatment initiation and are often not acknowledged by the prescribing physician, who may no longer be following the patient. The lack of widely accepted diagnostic criteria and symptom definitions may lead to underestimation of the incidence of severe side effects and of its toxicity. Unlike the underestimated risk of toxicity with amiodarone, severe complications associated with catheter ablation are usually directly ascribed to the treatment even by non-medical personnel, possibly resulting in overestimation of risks. This brief review will address the issue of amiodarone overuse and the frequent underestimation of its toxicity, while suggesting scenarios in which its use is entirely reasonable, and compare it with catheter ablation. 相似文献
5.
Ceder H. van den Bosch J. Tjomme van der Bruggen Florine N.J. Frakking Cecilia E.J. Terwisscha van Scheltinga Cornelis P. van de Ven Martine van Grotel Lianne M. Wellens Yvette G.T. Loeffen Marta Fiocco Marc H.W.A. Wijnen 《Journal of pediatric surgery》2019,54(9):1894-1900
BackgroundCentral venous access device (CVAD)-related complications are associated with high morbidity rates. This study was performed to underline the importance of CVAD-complication prevention and treatment.MethodsAn audit of practice of CVAD-related complications in pediatric oncology patients receiving a CVAD between January 2015 and June 2017 was performed. CVADs included were totally implantable venous access ports (TIVAPs), Hickman–Broviac® (HB), nontunneled, and peripherally inserted CVADs.ResultsA total of 201 children, with 307 CVADs, were analyzed. The incidence rates per 1000 CVAD-days for the most common complications were 1.66 for malfunctions, and 1.51 for central line-associated bloodstream infections (CLABSIs). Of all CVADs inserted, 37.1% were removed owing to complications, of which 45.6% were owing to CLABSIs. In 42% of the CLABSIs, the CLABSI could be successfully cured with systemic antibiotic treatment only. Of all included patients, 5.0% were admitted to the intensive care unit owing to CLABSI. The HB-CVAD compared to the TIVAP was a risk factor for CVAD-related complications, CLABSIs and dislocations in particular.ConclusionsThe incidence of CVAD-related complications is high. Research on the prevention and treatment of CVAD-related complications in pediatric oncology patients should be a high priority for all health care professionals.Type of studyPrognosis study (retrospective).Level of evidenceLevel II. 相似文献
6.
7.
8.
David F. Briceño Jackson J. Liang Yasuhiro Shirai Timothy M. Markman Andres Enriquez Aung Lin Pasquale Santangeli Michael P. Riley Robert D. Schaller Saman Nazarian David Lin Ramanan Kumareswaram Jeffery S. Arkles Mathew C. Hyman Gregory E. Supple David S. Frankel Fermin C. Garcia David J. Callans Sanjay Dixit 《Heart rhythm》2019,16(9):1421-1428
9.
《Radiologia》2019,61(6):510-513
We present a case of a female patient with ovarian cancer who had an inadvertent vascular access device implantation in the subclavian artery, being detected after 10 days. She was successfully treated with a covered stent without immediate complications. 相似文献
10.